Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + EBRT in CRPC with Limited Bone Metastases
NCT02484339Phase 2Unknown
- Sponsor
- University Hospital Freiburg
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by University Hospital Freiburg. Status: unknown.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02484339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484339.